Clinical Magnetic Resonance Spectroscopy

  • Paul Van Hecke
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

Since the early days of the introduction of magnetic resonance as a clinical imaging modality, magnetic resonance spectroscopy (MRS) has been earmarked as a potentially useful clinical tool, able to provide biochemical information of tissues in a completely non-invasive way. The penetration of the technique into the daily clinical diagnosis has however been much slower than expected from the initial enthusiasm. Still, the progress is slow, is steady, and the quantity and reproducibility of data acquired in a number of pathologies are such that MRS is now being included as a diagnostic or of as a follow-up procedure in some examinations, as an essential adjunct to MRI and other imaging techniques (Danielsen and Ross 1998, Young and Cecil Charles 1996).

Keywords

Human Immunodeficiency Virus Magnetic Resonance Spectroscopy Temporal Lobe Epilepsy Proton Magnetic Resonance Spectroscopy Magn Reson Image 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achten E, Boon P, Van-De Kerckhove T et al. (1997) Value of single-voxel proton MR spectroscopy in temporal lobe epilepsy. AJNR Am J Neuroradiol 18:1131–1139PubMedGoogle Scholar
  2. Achten E, Santens P, Boon P et al. (1998) Single-voxel proton MR spectroscopy and positron emission tomography for lateralization of refractory temporal lobe epilepsy [see comments). AJNR Am J Neuroradiol 19:1–8PubMedGoogle Scholar
  3. Alonso J, Rovira A, Capellades J et al. (1996) Cerebral proton spectroscopy of people infected with the human immunodeficiency virus. Med Clin Bare 107:361–365Google Scholar
  4. Arnold DL, Wolinsky JS, Matthews PM et al. (1998) The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 64 Suppl 1:S94–101Google Scholar
  5. Aotsuka A, Shinotoh H, Hattori T (1997) Magnetic resonance spectroscopy in Parkinson’s disease and multiple system atrophy. Nippon Rinsho 55:249–254PubMedGoogle Scholar
  6. Bartha R, Williamson PC, Drost DJ et al. (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 54:959–965PubMedGoogle Scholar
  7. Bergman AJ, Van-der Knaap MS, Smeitink JA et al. (1996) Magnetic resonance imaging and spectroscopy of the brain in propionic acidemia: clinical and biochemical considerations. Pediatr Res 40:404–409PubMedGoogle Scholar
  8. Berry I, Ranjeva JP, Duthil P et al. (1998a) Diffusion and perfusion MRI, measurements of acute stroke events and outcome: present practice and future hope. Cerebrovasc Dis 8 Suppl 2:8–16Google Scholar
  9. Berry I, Ranjeva JP, Manelfe C et al. (1998b) Magnetic resonance imaging of multiple sclerosis lesions. Rev Neurol (Paris) 154:607–617PubMedGoogle Scholar
  10. Bertolino A, Callicott JH, Elman I et al. (1998a) Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 43:641–648PubMedGoogle Scholar
  11. Bertolino A, Kumra S, Callicott JH et al. (1998b) Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am J Psychiatry 155:1376–1383PubMedGoogle Scholar
  12. Block W, Karitzky J, Traber F et al. (1998) Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements [see comments]. Arch Neurol 55:931–936PubMedGoogle Scholar
  13. Bluml S, Zuckerman E, Tan J et al. (1998) Proton-decoupled 31P magnetic resonance spectroscopy reveals osmotic and metabolic disturbances in human hepatic encephalopathy. J Neurochem 71:1564–1576PubMedGoogle Scholar
  14. Bluml S, Tan J, Harris K et al. (1999) Quantitative protondecoupled P-31 MRS of the schizophrenic brain in vivo. J Comput Assist Tomogr 23:272–275PubMedGoogle Scholar
  15. Brockmann K, Pouwels PJ, Christen HJ et al. (1996) Localized proton magnetic resonance spectroscopy of cerebral metabolic disturbances in children with neuronal ceroid lipofuscinosis. Neuropediatrics 27:242–248PubMedGoogle Scholar
  16. Brooks DJ (1997) Advances in imaging Parkinson’s disease [editorial]. Curr Opin Neurol 10:327–331PubMedGoogle Scholar
  17. Byrd SE, Tomita T, Palka PS et al. (1996) Magnetic resonance spectroscopy (MRS) in the evaluation of pediatric brain tumors. Part II: Clinical analysis. J Natl Med Assoc 88:717–723PubMedGoogle Scholar
  18. Cady EB (1996) Metabolite concentrations and relaxation in perinatal cerebral hypoxic-ischemic injury. Neurochem Res 21:1043–1052PubMedGoogle Scholar
  19. Callicott JH, Egan MF, Bertolino A et al. (1998) Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype. Biol Psychiatry 44:941–950PubMedGoogle Scholar
  20. Caplan LR (1997) New therapies for stroke. Arch Neurol 54:1222–1224PubMedGoogle Scholar
  21. Castillo M, Kwock L (1998) Proton MR spectroscopy of common brain tumors. Neuroimaging Clin North Am 8:733–752Google Scholar
  22. Cecil KM, Lenkinski RE (1998) Proton MR spectroscopy in inflammatory and infectious brain disorders. Neuroimaging Clin North Am 8:863–880Google Scholar
  23. Cecil KM, Lenkinski RE, Gur RE et al. (1999) Proton magnetic resonance spectroscopy in the frontal and temporallobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology 20:131–140PubMedGoogle Scholar
  24. Cendes F, Andermann F, Dubeau F et al. (1997a) Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology 49:1525–1533PubMedGoogle Scholar
  25. Cendes F, Caramanos Z, Andermann F et al. (1997b) Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporallobe epilepsy: a series of 100 patients. Ann Neurol 42:737–746PubMedGoogle Scholar
  26. Chang L, Ernst T, Tornatore C et al. (1997) Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 48:836–845PubMedGoogle Scholar
  27. Chang KH, Song IC, Kim SH et al. (1998) In vivo single-voxel proton MR spectroscopy in intracranial cystic masses [see comments]. AJNR Am J Neuroradiol 19:401–405PubMedGoogle Scholar
  28. Choe BY, Suh TS, Shinn KS et al. (1996) Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 31:345–352PubMedGoogle Scholar
  29. Choe BY, Park JW, Lee KS et al. (1998) Neuronal laterality in Parkinson’s disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest Radiol 33:450–455PubMedGoogle Scholar
  30. Chu WI, Hetherington HP, Kuzniecky RI et al. (1998) Lateralization of human temporal lobe epilepsy by 31P NMR spectroscopic imaging at 4.1 T. Neurology 51:472–479PubMedGoogle Scholar
  31. Clanet M, Berry I (1998) Magnetic resonance imaging in multiple sclerosis. Curr Opin Neurol 11:299–303PubMedGoogle Scholar
  32. Clark JM, Marks MP, Adalsteinsson E et al. (1996) MELAS: Clinical and pathologic correlations with MRI, xenon/CT, and MR spectroscopy. Neurology 46:223–227PubMedGoogle Scholar
  33. Clarke CE, Lowry M, Horsman A (1997) Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson’s disease measured by proton magnetic resonance spectroscopy. Mov Disord 12:297–301PubMedGoogle Scholar
  34. Connelly A, Van Paesschen W, Porter DA et al. (1998) Proton magnetic resonance spectroscopy in MRI-negative temporallobe epilepsy. Neurology 51:61–66PubMedGoogle Scholar
  35. Constantinidis I, Malko JA, Peterman SB et al. (1996) Evaluation of 1H magnetic resonance spectroscopic imaging as a diagnostic tool for the lateralization of epileptogenic seizure foci. Br J Radiol 69:15–24PubMedGoogle Scholar
  36. Cross JH, Connelly A, Jackson GD et al. (1996) Proton magnetic resonance spectroscopy in children with temporal lobe epilepsy. Ann Neurol 39:107–113PubMedGoogle Scholar
  37. Cross JH, Gordon I, Connelly A et al. (1997) Interictal 99Tc(m) HMPAO SPECT and 1H MRS in children with temporal lobe epilepsy. Epilepsia 38:338–345PubMedGoogle Scholar
  38. Cruz CJ, Aminoff MJ, Meyerhoff DJ et al. (1997) Proton MR spectroscopic imaging of the striatum in Parkinson’s disease. Magn Reson Imaging 15:619–624PubMedGoogle Scholar
  39. Cwik VA, Hanstock CC, Allen PS et al. (1998) Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 50:72–77PubMedGoogle Scholar
  40. Danielsen ER, Ross B (eds) (1998) Magnetic resonance spetroscopy diagnosis of neurological diseases. Marcel Dekker, New York BaselGoogle Scholar
  41. Davie CA, Barker GJ, Thompson AJ et al. (1997) 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiplesclerosis. J Neurol Neurosurg Psychiatry 63:736–742PubMedGoogle Scholar
  42. Davie C (1998) The role of spectroscopy in parkinsonism [editorial]. Mov Disord 13:2–4PubMedGoogle Scholar
  43. Deicken RF, Zhou L, Schuff N et al. (1997) Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophr Res 27:65–71PubMedGoogle Scholar
  44. Deicken RF, Zhou L, Schuff N et al. (1998) Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiatry 43:483–488PubMedGoogle Scholar
  45. De Stefano N, Matthews PM, Fu L et al. (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121:1469–1477PubMedGoogle Scholar
  46. Doyle VL, Barton SJ, Griffiths JR (1999) P-31 and H-1 MRS of human cancer. Curr Sci 76:772–776Google Scholar
  47. Dubowitz DJ, Bluml S, Arcinue E et al. (1998) MR of hypoxic encephalopathy in children after near drowning: correlation with quantitative proton MR spectroscopy and clinical outcome. AJNR Am J Neuroradiol 19:1617–1627PubMedGoogle Scholar
  48. Duc CO, Trabesinger AH, Weber OM et al. (1998) Quantitative H-1 MRS in the evaluation of mesial temporal lobe epilepsy in vivo. Magn Reson Imaging 16:969–979PubMedGoogle Scholar
  49. Duncan JS (1997) Imaging and epilepsy. Brain 120:339–377PubMedGoogle Scholar
  50. Ellis CM, Lemmens G, Williams SC et al. (1997) Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson’s disease: a proton magnetic resonance spectroscopy study. Neurology 49:438–444PubMedGoogle Scholar
  51. Ellis CM, Simmons A, Andrews C et al. (1998) A proton magnetic resonance spectroscopic study in ALS: Correlation with clinical findings. Neurology 51:1104–1109PubMedGoogle Scholar
  52. Ende GR, Laxer KD, Knowlton RC et al. (1997) Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging. Radiology 202:809–817Google Scholar
  53. Engelbrecht V, Rassek M, Gartner J et al. (1997a) The value of new MRI techniques in adrenoleukodystrophy. Pediatr Radiol 27:207–215PubMedGoogle Scholar
  54. Engelbrecht V, Rassek M, Huismann J et al. (1997b) MR and proton MR spectroscopy of the brain in hyperhomocysteinemia caused by methylenetetrahydrofolate reductase deficiency. AJNR Am J Neuroradiol 18:536–539PubMedGoogle Scholar
  55. Ernst T, Chang L, Melchor R et al. (1997) Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 203:829–836PubMedGoogle Scholar
  56. Falini A, Calabrese G, Origgi D et al. (1996) Proton magnetic resonance spectroscopy and intracranial tumours: clinical perspectives. J Neurol 243:706–714PubMedGoogle Scholar
  57. Falini A, Calabrese G. Filippi M et al. (1998) Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. AJNR Am J Neuroradiol 19:223–229PubMedGoogle Scholar
  58. Federico F, Simone IL, Conte C et al. (1996) Prognostic significance of metabolic changes detected by proton magnetic resonance spectroscopy in ischaemic stroke. J Neurol 243:241–247PubMedGoogle Scholar
  59. Federico F, Simone IL, Lucivero V et al. (1997a) Proton magnetic resonance spectroscopy in Parkinson’s disease and atypical parkinsonian disorders. Mov Disord 12:903–909PubMedGoogle Scholar
  60. Federico F, Simone IL, Lucivero V et al. (1997b) Proton magnetic resonance spectroscopy in Parkinson’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 62:239–242PubMedGoogle Scholar
  61. Fu L, Matthews PM, De Stefano N et al. (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121:103–113PubMedGoogle Scholar
  62. Fujimoto T, Nakano T, Takano T et al. (1996) Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia. Biol Psychiatry 40:14–18PubMedGoogle Scholar
  63. Fukuzako H, Fukuzako T, Takeuchi K et al. (1996) Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms. Prog Neuropsychopharmacol Biol. Psychiatry 20:629–640PubMedGoogle Scholar
  64. Furuya S, Naruse S, Ide M et al. (1997) Evaluation of metabolic heterogeneity in brain tumors using 1H-chemical shift imaging method. NMR Biomed 10:25–30PubMedGoogle Scholar
  65. Gadian DG, Leonard JV (1996) The role of magnetic resonance spectroscopy in the investigation of lactic acidosis and inborn errors of energy metabolism. J Inherit Metab Dis 19:548–552PubMedGoogle Scholar
  66. Gadian DG, Isaacs EB, Cross JH et al. (1996) Lateralization of brain function in childhood revealed by magnetic resonance spectroscopy. Neurology 46:974–977PubMedGoogle Scholar
  67. Ganesan V, Johnson A, Connelly A et al. (1997) Guanidinoacetate methyltransferase deficiency: new clinical features. Pediatr Neurol 17:155–157PubMedGoogle Scholar
  68. Garcia PA, Laxer KD, van-der Grond J et al. (1997) Correlation of seizure frequency with N-acetyl-aspartate levels determined by IH magnetic resonance spectroscopic imaging. Magn Reson Imaging 15:475–478PubMedGoogle Scholar
  69. Geissler A, Lock G, Frund R et al. (1997) Cerebral abnormalities in patients with cirrhosis detected by proton magneticresonance spectroscopy and magnetic resonance imaging. Hepatology 25:48–54PubMedGoogle Scholar
  70. Gideon P, Rosenbaum S, Sperling B et al. (1999) MR-visible brain water content in human acute stroke. Magn Reson Imaging 17:301–304PubMedGoogle Scholar
  71. Gillard JH, Barker PB, van Zijl PC et al. (1996) Proton MR spectroscopy in acute middle cerebral artery stroke. AJNR Am J Neuroradiol 17:873–886Google Scholar
  72. Girard N, Wang ZJ, Erbetta A et al. (1998) Prognostic value of proton MR spectroscopy of cerebral hemisphere tumors in children. Neuroradiology 40:121–125PubMedGoogle Scholar
  73. Giroud M, Walker P, Bernard D et al. (1996) Reduced brain Nacetyl-aspartate in frontal lobes suggests neuronal loss in patients with amyotrophic lateral sclerosis. Neurol Res 18:241–24PubMedGoogle Scholar
  74. Gonzalez RG, Guimaraes AR, Moore GJ et al. (1996) Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Alzheimer Dis Assoc Disord 10:46–52PubMedGoogle Scholar
  75. Goodkin K, Wilkie FL, Concha M et al. (1997) Subtle neuropsychological impairment and minor cognitive-motor disorder in HIV-1 infection. Neuroradiological, neurophysiological, neuroimmunological, and virological correlates. Neuroimaging Clin North Am 7:561–579Google Scholar
  76. Gotsis ED, Fountas K, Kapsalaki E et al. (1996) In vivo proton MR spectroscopy: the diagnostic possibilities of lipid resonances in brain tumors. Anticancer Res 16:1565–1567PubMedGoogle Scholar
  77. Grand S, Esteve F, Remy C et al. (1997) Proton magnetic resonance spectroscopy: a metabolic approach of cerebral tumors and their follow-up after external radiation therapy. Rev Med Interne 18:865–875PubMedGoogle Scholar
  78. Gredal O, Rosenbaum S, Topp S et al. (1997) Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 48:878–881PubMedGoogle Scholar
  79. Groenendaal F., van-der Grond J., van Haastert I.C. et al. (1996) Findings in cerebral proton spin resonance spectroscopy in newborn infants with asphyxia, and psychomotor development. Ned Tijdschr Geneeskd 140:255–259PubMedGoogle Scholar
  80. Gupta RK, Roy R, Dev R et al. (1996) Finger printing of Mycobacterium tuberculosis in patients with intracranial tuberculomas by using in vivo, ex vivo, and in vitro magnetic resonance spectroscopy. Magn Reson Med 36:829–833PubMedGoogle Scholar
  81. Gupta RK, Roy R (1999) Magnetic resonance imaging and spectroscopy of intracranial tuberculomas. Curr Sci 76:783–788Google Scholar
  82. Hagberg G (1998) From magnetic resonance spectroscopy to classification of tumors. A review of pattern recognition methods. NMR Biomed 11:148–156PubMedGoogle Scholar
  83. Hajek M, Dezortova M, Komarek V (1998) 1H MR spectroscopy in patients with mesial temporal epilepsy. MAGMA 7:95–114PubMedGoogle Scholar
  84. Hanrahan JD, COX IJ, Edwards AD et al. (1998) Persistent increases in cerebral lactate concentration after birth asphyxia. Pediatr Res 44:304–311PubMedGoogle Scholar
  85. Harada M, Miyoshi H, Ootsuka H et al. (1997) Accuracy and clinical utility of quantitative proton magnetic resonance spectroscopy (MRS) on phantom and chronic cerebral ischemia.Nippon Igaku Hoshasen Gakkai Zasshi 57:487–492PubMedGoogle Scholar
  86. Harrison MJ, Newman SP, Hall CM et al. (1998) Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study. J Neurol Neurosurg Psychiatry 65:301–307PubMedGoogle Scholar
  87. Haseler LJ, Sibbitt WL, Mojtahedzadeh HN et al. (1998) Proton MR spectroscopic measurement of neurometabolites in hepatic encephalopathy during orallactulose therapy. AJNR Am J Neuroradiol 19:1681–1686PubMedGoogle Scholar
  88. Heimberg C, Komoroski RA, Lawson WB et al. (1998) Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res 83:105–115PubMedGoogle Scholar
  89. Heun R, Schlegel S, Graf MM et al. (1997) Proton magnetic resonance spectroscopy in dementia of Alzheimer type. Int J Geriatr Psychiatry 12:349–358PubMedGoogle Scholar
  90. Hinsberger AD, Williamson PC, Carr TJ et al. (1997) Magnetic resonance imaging volumetric and phosphorus 31 magnetic resonance spectroscopy measurements in schizophrenia. J Psychiatry Neurosci 22:111–117PubMedCentralPubMedGoogle Scholar
  91. Hirsch JA, Lenkinski RE, Grossman RI (1996) MR spectroscopy in the evaluation of enhancing lesions in the brain in multiple sclerosis. AJNR Am J Neuroradiol 17:1829–1836PubMedGoogle Scholar
  92. Holopainen IE, Lundbom NM, Metsahonkala EL et al. (1997) Temporal lobe pathology in epilepsy: proton magnetic resonance spectroscopy and positron emission tomography study. Pediatr Neurol 16:98–104PubMedGoogle Scholar
  93. Holopainen IE, Valtonen ME, Komu ME et al. (1998) Proton spectroscopy in children with epilepsy and febrile convulsions. Pediatr Neurol 19:93–99PubMedGoogle Scholar
  94. Huda A, Guze BH, Thomas MA et al. (1998) Clinical correlation of neuropsychological tests with H-1 magnetic resonance spectroscopy in hepatic encephalopathy. Psychosom Med 60:550–556PubMedGoogle Scholar
  95. Huemer M, Muehl A, Wandl VK et al. (1998) Stroke-like encephalopathy in an infant with 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency. Eur J Pediatr 157:743–746PubMedGoogle Scholar
  96. Hugg JW, Kuzniecky RI, Gilliam FG et al. (1996) Normalization of contralateral metabolic function following temporallobectomy demonstrated by 1H magnetic resonance spectroscopic imaging. Ann Neurol 40:236–239PubMedGoogle Scholar
  97. Huppi PS, Barnes PD (1997) Magnetic resonance techniques in the evaluation of the newborn brain. Clin Perinatol 24:693–723PubMedGoogle Scholar
  98. Hwang JH, Graham GD, Behar KL et al. (1996) Short echo time proton magnetic resonance spectroscopic imaging of macromolecule and metabolite signal intensities in the human brain. Magn Reson Med 35:633–639PubMedGoogle Scholar
  99. Iranzo A, Moreno A, Pujol J et al. (1999) Proton magnetic resonance spectroscopy pattern of progressive multifocal leukoencephalopathy in AIDS. J Neurol Neurosurg Psychiatry 66:520–523PubMedGoogle Scholar
  100. Jackson GD, Connelly A (1996) Magnetic resonance imaging and spectroscopy. Curr Opin Neurol 9:82–88PubMedGoogle Scholar
  101. Jarvik JG, Lenkinski RE, Saykin AJ et al. (1996) Proton spectroscopy in asymptomatic HIV-infected adults: initial results in a prospective cohort study. J Acquir Immune Defic Syndr Hum Retrovirol 13:247–253PubMedGoogle Scholar
  102. Kaibara T, Tyson RL, Sutherland GR (1998) Human cerebral neoplasms studied using MR spectroscopy: a review. Biochem Cell Biol 76:477–486PubMedGoogle Scholar
  103. Kalra S, Cashman NR, Genge A et al. (1998) Recovery of Nacetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9:1757–1761PubMedGoogle Scholar
  104. Kamada K, Houkin K, Iwasaki Y et al. (1997) Metabolic and neurological patterns in chronic cerebral infarction: a single-voxel 1H-MR spectroscopy study. Neuroradiology 39:560–565PubMedGoogle Scholar
  105. Kattapong VJ, Brooks WM, Wesley MH et al. (1996) Proton magnetic resonance spectroscopy of vascular-and Alzheimer-type dementia. Arch Neurol 53:678–680PubMedGoogle Scholar
  106. Kegeles LS, Humaran TJ, Mann JJ (1998) In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol Psychiatry 44:382–398PubMedGoogle Scholar
  107. King D, Batuch GH (1998) Magnetic resonance imaging and temporal lobe epilepsy. Acta Neurol Scand 98:217–223PubMedGoogle Scholar
  108. Kizu O, Naruse S, Furuya S et al. (1998) Application of proton chemical shift imaging in monitoring of gamma knife radiosurgery on brain tumors. Magn Reson Imaging 16:197–204PubMedGoogle Scholar
  109. Knowlton RC, Laxer KD, Ende G et al. (1997) Presurgical multimodality neuroimaging in electroencephalographic lateralized temporal lobe epilepsy. Ann Neurol 42:829–837PubMedCentralPubMedGoogle Scholar
  110. Korenke GC, Pouwels PJ, Frahm J et al. (1996) Arrested cerebral adrenoleukodystrophy: a clinical and proton magnetic resonance spectroscopy study in three patients. Pediatr Neurol 15:103–107PubMedGoogle Scholar
  111. Kostler H (1998) Proton magnetic resonance spectroscopy in portal-systemic encephalopathy. Metab Brain Dis 13:291–301PubMedGoogle Scholar
  112. Kugel H, Heindel W, Roth B et al. (1998) Proton MR spectroscopy in infants with cerebral energy deficiency due to hypoxia and metabolic disorders. Acta Radiol 39:701–710PubMedGoogle Scholar
  113. Kuzniecky R (1997) Magnetic resonance and functional magnetic resonance imaging: tools for the study of human epilepsy. Curr Opin Neurol 10:88–91PubMedGoogle Scholar
  114. Kuzniecky R, Hugg JW, Hetherington H et al. (1998) Relative utility of lH spectroscopic imaging and hippocampal volumetry in the lateralization of mesial temporal lobe epilepsy. Neurology 51:66–71PubMedGoogle Scholar
  115. Lam WW, Wang ZJ, Zhao H et al. (1998) IH MR spectroscopy of the basal ganglia in childhood: a semiquantitative analysis. Neuroradiology 40:315–323PubMedGoogle Scholar
  116. Landtblom AM, Sjoqvist L, Soderfeldt B et al. (1996) Proton MR spectroscopy and MR imaging in acute and chronic multiple sclerosis-ringlike appearances in acute plaques. Acta Radiol 37:278–287PubMedGoogle Scholar
  117. Laubenberger J, Haussinger D, Bayer S et al. (1996) HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times. Radiology 199:805–810PubMedGoogle Scholar
  118. Laubenberger I, Haussinger D, Bayer S et al. (1997) Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis [see comments]. Gastroenterology 112:1610–1616PubMedGoogle Scholar
  119. Lauriero F, Federico F, Rubini G et al. (1996) 99Tcm-HMPAO SPET and 1H-MRS (proton magnetic resonance spectroscopy) in patients with ischaemic cerebral infarction. Nucl Med Commun 17:140–146PubMedGoogle Scholar
  120. Laxer K.D. (1997) Clinical applications of magnetic resonance spectroscopy. Epilepsia 38 Suppl 4:S13–S17Google Scholar
  121. Lazareff JA, Bockhorst KH, Curran I et al. (1998) Pediatric low-grade gliomas: prognosis with proton magnetic resonance spectroscopic imaging. Neurosurgery 43:809–817PubMedGoogle Scholar
  122. Lim KO, Adalsteinsson E, Spielman D et al. (1998) Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatry 55:346–352PubMedGoogle Scholar
  123. Lopez VD, Lenkinski RE, Frank I (1997) Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. Proc Natl Acad Sci USA 94:9854–9859Google Scholar
  124. Lorek AK, Penrice JM, Cady EB et al. (1996) Cerebral energy metabolism in isovaleric acidaemia. Arch Dis Child Fetal Neonatal Ed 74:F211–F213PubMedGoogle Scholar
  125. Lu D, Pavlakis SG, Frank Y et al. (1996) Proton MR spectroscopy of the basal ganglia in healthy children and children with AIDS. Radiology 199:423–428PubMedGoogle Scholar
  126. Lu D, Margouleff C, Rubin E et al. (1997) Temporal lobe epilepsy: correlation of proton magnetic resonance spectroscopy and 18F-fluorodeoxyglucose positron emission tomography. Magn Reson Med 37:18–23PubMedGoogle Scholar
  127. McClure RJ, Keshavan MS, Pettegrew JW (1998) Chemical and physiologic brain imaging in schizophrenia. Psychiatr Clin North Am 21:93–122PubMedGoogle Scholar
  128. MacKay S, Ezekiel F, Di SV et al. (1996) Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 198:537–545PubMedCentralPubMedGoogle Scholar
  129. Mader I, Roser W, Hagberg G et al. (1996) Proton chemical shift imaging, metabolic maps, and single voxel spectroscopy of glial brain tumors. MAGMA 4:139–150PubMedGoogle Scholar
  130. Maldonado X, Alonso J, Giralt J et al. (1998) 31 Phosphorus magnetic resonance spectroscopy in the assessment of head and neck tumors. Int J Radiat Oncol Biol Phys 40:309–312PubMedGoogle Scholar
  131. Marcus CD, Taylor RS, Sargentoni J et al. (1998) 1H MR spectroscopy of the brain in HIV-1-seropositive subjects: evidence for diffuse metabolic abnormalities. Metab Brain Dis 13:123–136PubMedGoogle Scholar
  132. Martin E, Buchli R, Ritter S et al. (1996) Diagnostic and prognostic value of cerebral 31 P magnetic resonance spectroscopy in neonates with perinatal asphyxia. Pediatr Res 40:749–758PubMedGoogle Scholar
  133. Matthews PM, Pioro E, Narayanan S et al. (1996) Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 119:715–722PubMedGoogle Scholar
  134. Matthews PM, De Stefano N, Narayanan S et al. (1998) Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 18:327–336PubMedGoogle Scholar
  135. Mathews VP, Barker PB, Blackband SI et al. (1995) Cerebral metabolites in patients with acute and subacute strokes: concentrations determined by quantitative proton MR spectroscopy. AIR Am J Roentgenol 165:633–638Google Scholar
  136. Meyerhoff DJ, Bloomer C, Cardenas V et al. (1999) Elevated subcortical choline metabolites in cognitively and clinicallyc asymptomatic HIV + patients. Neurology 52:995–1003PubMedGoogle Scholar
  137. Miller DH, Albert PS, Barkhof F et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 39:6–16PubMedGoogle Scholar
  138. Miller DH, Grossman RI, Reingold SC et al. (1998) The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121:3–24PubMedGoogle Scholar
  139. Moller HE, Weglage J, Wiedermann D et al. (1997) Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo. Brain Res 778:329–337PubMedGoogle Scholar
  140. Moller HE, Weglage J, Wiedermann D et al. (1998) Bloodbrain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J Cereb Blood Flow Metab 18:1184–1191PubMedGoogle Scholar
  141. Moller HE, Vermathen P, Lentschig MG et al. (1999) Metabolic characterization of AIDS dementia complex by spectroscopic imaging. I Magn Reson Imaging 9:10–18Google Scholar
  142. Morgan MY (1996) Noninvasive neuroinvestigation in liver disease. Semin Liver Dis 16:293–314PubMedGoogle Scholar
  143. Morishita H, Naruse S, Furuya S et al. (1997) Evaluation of cerebral ischemia with metabolic image by using 3D-CSIcomparing with SPECT and PET. Nippon Rinsho 55:1762–1767PubMedGoogle Scholar
  144. Nagele T, Seeger U, Pereira P et al. (1999) Proton magnetic resonance spectroscopy to monitor the concentration changes of cerebral metabolites after TIPS implantation. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 170:298–303PubMedGoogle Scholar
  145. Narayana PA, Doyle TJ, Lai D et al. (1998) Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 43:56–71PubMedGoogle Scholar
  146. Negendank WG, Sauter R, Brown TR et al. (1996) Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 84:449–458PubMedGoogle Scholar
  147. Novotny EJ, Hyder F, Shevell M et al. (1999) GABA changes with vigabatrin in the developing human brain. Epilepsia 40:462–466PubMedGoogle Scholar
  148. Paley M, Cozzone PJ, Alonso J et al. (1996) A multicenter proton magnetic resonance spectroscopy study of neurological complications of AIDS. AIDS Res Hum Retroviruses 12:213–222PubMedGoogle Scholar
  149. Pan JW, Hetherington HP, Vaughan JT et al. (1996) Evaluation of multiple sclerosis by 1 H spectroscopic imaging at 4.1 T. Magn Reson Med 36:72–77PubMedGoogle Scholar
  150. Parnetti L, Tarducci R, Presciutti O et al. (1997) Proton magnetic resonance spectroscopy can differentiate Alzheimer’s disease from normal aging. Mech Ageing Dev 97:9–14PubMedGoogle Scholar
  151. Pavlakis SG, Kingsley PB, Kaplan GP et al. (1998) Magnetic resonance spectroscopy: use in monitoring MELAS treatment. Arch Neurol 55:849–852PubMedGoogle Scholar
  152. Pavlakis SG, Lu D, Frank Y et al. (1998) Brain lactate and Nacetylaspartate in pediatric AIDS encephalopathy. AINR Am J Neuroradiol 19:383–385Google Scholar
  153. Penrice J, Cady EB, Lorek A et al. (1996) Proton magnetic resonance spectroscopy of the brain in normal preterm and term infants, and early changes after perinatal hypoxia-ischemia. Pediatr Res 40:6–14PubMedGoogle Scholar
  154. Pettegrew JW, Klunk WE, Panchalingam K et al. (1997) Magnetic resonance spectroscopic changes in Alzheimer’s disease. Ann NY Acad Sci 826:282–306PubMedGoogle Scholar
  155. Petroff OA, Rothman DL, Behar KL et al. (1996) The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 39:95–99PubMedGoogle Scholar
  156. Petroff OA, Mattson RH, Behar KL et al. (1998) Vigabatrin increases human brain homo carnosine and improves seizure control. Ann Neurol 44:948–952PubMedGoogle Scholar
  157. Petroff OA, Hyder F, Mattson RH et al. (1999a) Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy [see comments]. Neurology 52:473–478PubMedGoogle Scholar
  158. Petroff OAC, Rothman DL, Behar KL et al. (1999b) Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Seizure 8:120–127PubMedGoogle Scholar
  159. Pietz J, Kreis R, Schmidt H et al. (1996) Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. Radiology 201:413–420PubMedGoogle Scholar
  160. Pietz J, Kreis R, Rupp A et al. (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Investig 103:1169–1178PubMedGoogle Scholar
  161. Pioro EP (1997) MR spectroscopy in amyotrophic lateral sclerosis/motor neuron disease. J Neurol Sci 152 Suppl 1:S49–S53Google Scholar
  162. Potwarka JJ, Drost DJ, Williamson PC et al. (1999) A H-Idecoupled P-31 chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biol Psychiatry 45:687–693PubMedGoogle Scholar
  163. Pouwels PJ, Kruse B, Korenke GC et al. (1998) Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics 29:254–264PubMedGoogle Scholar
  164. Prost R, Haughton V, Li SJ (1997) Brain tumors: localized HI MR spectroscopy at 0.5 T. Radiology 204:235–238PubMedGoogle Scholar
  165. Rajanayagam V, Grad J, Krivit W et al. (1996) Proton MR spectroscopy of childhood adrenoleukodystrophy. AJNR Am J Neuroradiol 17:1013–1024PubMedGoogle Scholar
  166. Rajanayagam V, Balthazor M, Shapiro EG et al. (1997) Proton MR spectroscopy and neuropsychological testing in adrenoleukodystrophy. AJNR Am J Neuroradiol 18:1909–1914PubMedGoogle Scholar
  167. Remy C, Grand S, Lai ES et al. (1995) 1H MRS of human brain abscesses in vivo and in vitro. Magn Reson Med 34:508–514PubMedGoogle Scholar
  168. Rooney WD, Goodkin DE, Schuff N et al. (1997) 1H MRSI of normal appearing white matter in multiple sclerosis. Mult Scler 3:231–237PubMedGoogle Scholar
  169. Rooney WD, Miller RG, Gelinas D et al. (1998) Decreased Nacetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 50:1800–1805PubMedGoogle Scholar
  170. Rose SE, de-Zubicaray GI, Wang D et al. (1999) A 1H MRS study of probable Alzheimer’s disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 17:291–299PubMedGoogle Scholar
  171. Ross BD Danielsen ER Bluml S (1996) Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy-Dig Dis 14 Suppl 1:30–3Google Scholar
  172. Saliba E, Barantin L, Akoka S et al. (1997) Circulation and cerebral metabolism in neonatal hypoxia-ischemia. J Gynecol Obstet Biol Reprod Paris 26:465–469PubMedGoogle Scholar
  173. Salvan AM, Vion DJ, Confort GS et al. (1997a) Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy. AIDS Res Hum Retroviruses 13:1055–1066PubMedGoogle Scholar
  174. Salvan AM, Vion DJ, Confort GS et al. (1997b) Cerebral metabolic alterations in human immunodeficiency virus-related encephalopathy detected by proton magnetic resonance spectroscopy. Comparison between sequences using short and long echo times. Invest Radiol 32:485–495PubMedGoogle Scholar
  175. Salvan AM, Lamoureux S, Michel G et al. (1998) Localized proton magnetic resonance spectroscopy of the brain in children infected with human immunodeficiency virus with and without encephalopathy. Pediatr Res 44:755–762PubMedGoogle Scholar
  176. Sarchielli P, Presciutti O, Pelliccioli GP et al. (1999) Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 122 Part 3:513–521Google Scholar
  177. Sarchielli P, Presciutti O, Tarducci R et al. (1998) IH-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-la: results of a preliminary study. J Neurol Neurosurg Psychiatry 64:204–212PubMedGoogle Scholar
  178. Saunders DE, Howe FA, van-den Boogaart A et al. (1997) Discrimination of metabolite from lipid and macromolecule resonances in cerebral infarction in humans using short echo proton spectroscopy. J Magn Reson Imaging 7:1116–1121PubMedGoogle Scholar
  179. Schiepers C, Van Hecke P, Vandenberghe R et al. (1997) Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler 3:8–17PubMedGoogle Scholar
  180. Seitz D, Grodd W, Schwab A et al. (1998) MR imaging and localized proton MR spectroscopy in late infantile neuronal ceroid lipofuscinosis. AJNR Am J Neuroradiol 19:1373–1377PubMedGoogle Scholar
  181. Shimizu H, Kumabe T, Tominaga T et al. (1996) Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am J Neuroradiol 17:737–747PubMedGoogle Scholar
  182. Shioiri T, Hamakawa H, Kato T et al. (1996) Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: a preliminary report. Schizophr Res 22:19–26PubMedGoogle Scholar
  183. Schuff N, Amend D, Ezekiel F et al. (1997) Changes of hippocampal N-acetyl aspartate and volume in Alzheimer’s disease. A proton MR spectroscopic imaging and MRI study. Neurology 49:1513–1521PubMedGoogle Scholar
  184. Schuff N., Amend D.L., Meyerhoff D.J. et al. (1998) Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology 207:91–102PubMedCentralPubMedGoogle Scholar
  185. Schulze A, Hess T, Wevers R et al. (1997) Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: diagnostic tools for a new inborn error of metabolism [see comments]. J Pediatr 131:626–631PubMedGoogle Scholar
  186. Schurmann M, Engelbrecht V, Lohmeier K et al. (1997) Cerebral metabolic changes in biotinidase deficiency. J Inherit Metab Dis 20:755–760PubMedGoogle Scholar
  187. Simone IL, Federico F, Tortorella C et al. (1998) Localised 1HMR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J Neurol Neurosurg Psychiatry 64:516–523PubMedGoogle Scholar
  188. Sitoh YY, Tien RD (1998) Neuroimaging in epilepsy. J Magn Reson Imaging 8:277–288PubMedGoogle Scholar
  189. Speck O, Thiel T, Hennig J (1996) Grading and therapy monitoring of astrocytomas with 1H-spectroscopy: preliminary study. Anticancer Res 16:1581–1585PubMedGoogle Scholar
  190. Sperl W, Felber S, Skladal D et al. (1997) Metabolic stroke in carbamyl phosphate synthetase deficiency. Neuropediatrics 28:229–234PubMedGoogle Scholar
  191. Stanley JA, Williamson PC, Drost DJ et al. (1996) An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull 22:597–609PubMedGoogle Scholar
  192. Stanley JA, Cendes F, Dubeau F et al. (1998) Proton magnetic resonance spectroscopic imaging in patients with extratemporal epilepsy. Epilepsia 39:267–273PubMedGoogle Scholar
  193. Stockier S, Hanefeld F (1997) Guanidinoacetate methyltransferase deficiency: a newly recognized inborn error of creatine biosynthesis. Wien Klin Wochenschr 109:86–88Google Scholar
  194. Sutton LN, Wang ZJ, Wehrli SL et al. (1997) Proton spectroscopy of suprasellar tumors in pediatric patients. Neurosurgery 41:388–394PubMedGoogle Scholar
  195. Taylor JS, Langston JW, Reddick WE et al. (1996) Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 36:1251–1261PubMedGoogle Scholar
  196. Taylor JS, Ogg RJ, Langston JW (1998) Proton MR spectroscopy of pediatric brain tumors. Neuroimaging Clin North Am 8:753–779Google Scholar
  197. Taylor RS, Turjanski N, Bhattacharya S et al. (1999) A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson’s disease. Metab Brain Dis 14:45–55Google Scholar
  198. Tedeschi G, Bertolino A, Lundbom N et al. (1996) Cortical and subcortical chemical pathology in Alzheimer’s disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology 47:696–704PubMedGoogle Scholar
  199. Tedeschi G, Litvan I, Bonavita S et al. (1997a) Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson’s disease and corticobasal degeneration. Brain 120:1541–1552PubMedGoogle Scholar
  200. Tedeschi G, Lundbom N, Raman R et al. (1997b) Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 87:516–524PubMedGoogle Scholar
  201. Thomas MA, Huda A, Guze B et al. (1998a) Cerebral 1H MR spectroscopy and neuropsychologic status of patients with hepatic encephalopathy. AJR Am J Roentgenol 171:1123–1130PubMedGoogle Scholar
  202. Thomas MA, Ke Y, Levitt J et al. (1998b) Preliminary study of frontal lobe 1H MR spectroscopy in childhood-onset schizophrenia. J Magn Reson Imaging 8:841–846PubMedGoogle Scholar
  203. Thompson JE, Castillo M, Kwock L et al. (1998) Usefulness of proton MR spectroscopy in the evaluation of temporal lobe epilepsy. AJR Am J Roentgenol 170:771–776PubMedGoogle Scholar
  204. Tien RD, Lai PH, Smith JS et al. (1996) Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors. AJR Am J Roentgenol 167:201–209PubMedGoogle Scholar
  205. Tomoi M, Kimura H, Yoshida M et al. (1997) Alterations of lactate (+lipid) concentration in brain tumors with in vivo hydrogen magnetic resonance spectroscopy during radiotherapy. Invest Radiol 32:288–296PubMedGoogle Scholar
  206. Tourbah A, Stievenart JL, Iba ZM et al. (1996) In vivo localized NMR proton spectroscopy of normal appearing white matter in patients with multiple sclerosis. J Neuroradiol 23:49–55PubMedGoogle Scholar
  207. Tourbah A, Stievenart JL, Iba ZM et al. (1997) Localized proton magnetic resonance spectroscopy in patients with adult adrenoleukodystrophy. Increase of choline compounds in normal appearing white matter. Arch Neurol 54:586–592PubMedGoogle Scholar
  208. Tracey I, Carr CA, Guimaraes AR et al. (1996) Brain cholinecontaining compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: A proton magnetic resonance spectroscopic study [published erratum appears in Neurology 1996 Jun;46(6):1787]. Neurology 46:783–788PubMedGoogle Scholar
  209. Tzika AA, Vigneron DB, Dunn RS et al. (1996) Intracranial tumors in children: small single-voxel proton MR spectroscopy using short-and long-echo sequences. Neuroradiology 38:254–263PubMedGoogle Scholar
  210. van der Grond J, Balm R, Klijn CJ et al. (1996) Cerebral metabolism of patients with stenosis of the internal carotid artery before and after endarterectomy. J Cereb Blood Flow Metab 16:320–326PubMedGoogle Scholar
  211. van der Grond J, Gerson JR, Laxer KD et al. (1998) Regional distribution of interictal 31P metabolic changes in patients with temporal lobe epilepsy. Epilepsia 39:527–536PubMedCentralPubMedGoogle Scholar
  212. van der Grond J, Mali WP (1998) Multifunctional magnetic resonance imaging of cerebrovascular disease. Eur Radiol 8:726–738PubMedGoogle Scholar
  213. van der Grond J, van-Everdingen KJ, Eikelboom BC et al. (1999) Assessment of borderzone ischemia with a combined MR imaging-MR angiography-MR spectroscopy protocol. J Magn Reson Imaging 9:1–9PubMedGoogle Scholar
  214. van-der Knaap M, Bakker HD, Valk J (1998) MR imaging and proton spectroscopy in 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency. AJNR Am J Neuroradiol 19:378–382PubMedGoogle Scholar
  215. Vermathen P, Ende G, Laxer KD et al. (1997) Hippocampal Nacetylaspartate in neocortical epilepsy and mesial temporallobe epilepsy. Ann Neurol 42:194–199PubMedGoogle Scholar
  216. Vion DJ, Salvan AM, Confort GS et al. (1998) Brain proton magnetic resonance spectroscopy. Indications for diagnosis and follow-up of HIV-related encephalopathy in the adult. Presse Med 27:1398–1405Google Scholar
  217. Volz HP, Rzanny R, Rossger G et al. (1998) 31 Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics-a study including 50 patients and 36 controls. Biol Psychiatry 44:399–404PubMedGoogle Scholar
  218. Waldrop SM, Davis PC, Padgett CA et al. (1998) Treatment of brain tumors in children is associated with abnormal MR spectroscopic ratios in brain tissue remote from the tumor site [see comments]. AJNR Am J Neuroradiol 19:963–970PubMedGoogle Scholar
  219. Wang ZJ, Zimmerman RA (1998) Proton MR spectroscopy of pediatric brain metabolic disorders. Neuroimaging Clin North Am 8:781–807Google Scholar
  220. Wardlaw JM, Marshall I, Wild J et al. (1998) Studies of acute ischemic stroke with proton magnetic resonance spectroscopy: relation between time from onset, neurological deficit, metabolite abnormalities in the infarct, blood flow, and clinical outcome. Stroke 29:1618–1624PubMedGoogle Scholar
  221. Weber OM, Verhagen A, Duc CO et al. (1999) Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. Magn Reson Imaging 17:417–425PubMedGoogle Scholar
  222. Wilkinson ID, Lunn S, Miszkiel KA et al. (1997a) Proton MRS and quantitative MRI assessment of the short term neurological response to antiretroviral therapy in AIDS. J Neurol Neurosurg Psychiatry 63:477–482PubMedGoogle Scholar
  223. Wilkinson ID, Miller RF, Miszkiel KA et al. (1997b) Cerebral proton magnetic resonance spectroscopy in asymptomatic HIV infection. AIDS 11:289–295PubMedGoogle Scholar
  224. Woermann FG, McLean MA, Bartlett PA et al. (1999) Short echo time single-voxel IH magnetic resonance spectroscopy in magnetic resonance imaging-negative temporal lobe epilepsy: different biochemical profile compared with hippocampal sclerosis. Ann Neurol 45:369–376PubMedGoogle Scholar
  225. Yoshino E, Ohmori Y, Imahori Y et al. (1996) Irradiation effects on the metabolism of metastatic brain tumors: analysis by positron emission tomography and IH-magnetic resonance spectroscopy. Stereotact Funct Neurosurg 66 Suppl 1:240–259Google Scholar
  226. Young IR, Cecil Charles H (eds) (1996) MR spectroscopy-clinical applications and techniques. Martin Dunitz, LondonGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Paul Van Hecke
    • 1
  1. 1.Department of RadiologyUniversity HospitalsLeuvenBelgium

Personalised recommendations